Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effects of Alpha Lipoic Acid and Its Derivative “Andrographolid-Lipoic Acid-1” on Ulcerative Colitis: A Systematic Review With Meta-Analysis of Animal Studies Publisher Pubmed



Moeinian M1 ; Abdolghaffari AH1, 2, 3 ; Nikfar S1, 4 ; Momtaz S1, 2 ; Abdollahi M1, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Toxicology and Diseases Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran
  3. 3. Gastrointestinal Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  4. 4. Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Cellular Biochemistry Published:2019


Abstract

We aimed to review and meta-analyze the inflammatory and oxidative factors following alpha lipoic acid (ALA) and its derivative “andrographolid-lipoic acid-1” (AL-1) in ulcerative colitis (UC). ALA plays an important role in scavenging intracellular radicals and inflammatory elements. AL-1 is found in herbal medicines with potent anti-inflammatory properties. Data were collected from the Google Scholar, PubMed, Scopus, Evidence-based medicine/clinical trials, and Cochrane library database until 2017, which finally resulted in 22 animal studies (70 rats and 162 mice). The beneficial effects of ALA or AL-1 on the most important parameters of UC were reviewed; also, studies were considered separately in mice and rats. Administration of ALA and AL-1 significantly reduced the tumor necrosis factor-α level compared with the controls, while data were not noteworthy in the meta-analysis (mean differences = −18.57 [95% CI = −42.65 to 5.51], P = 0.13). In spite of insignificant decrease in meta-analysis outcomes (differences = 6.92 [95% CI = −39.33 to 53.16], P = 0.77), a significant reduction in myeloperoxidase activity was shown following ALA or AL-1 treatment compared with the controls. Despite significant differences in each study, we had to exclude some studies to homogenize data for meta-analyzing as they showed insignificant results. Interleukin 6, cyclooxygenase-2, glutathione, malondialdehyde, superoxide dismutase, histopathological score, macroscopic and microscopic scores, disease activity index, body weight change, and colon length were also reviewed. Most studies have emphasized on significant positive effects of ALA and AL-1. Comprehensive clinical trials are obligatory to determine the precious position of ALA or AL-1 in the management of UC. © 2018 Wiley Periodicals, Inc.
Other Related Docs
26. Targeting Metabolic Disorders by Natural Products, Journal of Diabetes and Metabolic Disorders (2015)
36. The Role of Melatonin on Chemotherapy-Induced Reproductive Toxicity, Journal of Pharmacy and Pharmacology (2018)
39. Potential Vaccines for Treating Crohn's Disease, Iranian Biomedical Journal (2020)